CG Oncology, Inc. (CGON)
62.22
+0.29
(+0.47%)
USD |
NASDAQ |
Oct 21, 16:00
62.22
0.00 (0.00%)
After-Hours: 17:08
CG Oncology Enterprise Value : 4.449B for Oct. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 20, 2026 | 4.449B |
| October 19, 2026 | 4.275B |
| October 16, 2026 | 4.266B |
| October 15, 2026 | 4.443B |
| October 14, 2026 | 4.441B |
| October 13, 2026 | 4.491B |
| October 12, 2026 | 4.555B |
| October 09, 2026 | 4.616B |
| October 08, 2026 | 4.567B |
| October 07, 2026 | 4.489B |
| October 06, 2026 | 4.600B |
| October 05, 2026 | 5.048B |
| October 02, 2026 | 4.931B |
| October 01, 2026 | 5.016B |
| September 30, 2026 | 5.241B |
| September 29, 2026 | 5.208B |
| September 28, 2026 | 5.128B |
| September 25, 2026 | 4.910B |
| September 24, 2026 | 5.052B |
| September 23, 2026 | 5.459B |
| September 22, 2026 | 5.845B |
| September 21, 2026 | 5.891B |
| September 18, 2026 | 5.570B |
| September 17, 2026 | 5.658B |
| September 16, 2026 | 5.526B |
| Date | Value |
|---|---|
| September 15, 2026 | 5.387B |
| September 14, 2026 | 5.497B |
| September 11, 2026 | 5.370B |
| September 10, 2026 | 5.339B |
| September 09, 2026 | 5.335B |
| September 08, 2026 | 5.462B |
| September 04, 2026 | 5.574B |
| September 03, 2026 | 5.544B |
| September 02, 2026 | 5.567B |
| September 01, 2026 | 5.679B |
| August 31, 2026 | 5.618B |
| August 28, 2026 | 5.545B |
| August 27, 2026 | 5.958B |
| August 26, 2026 | 5.906B |
| August 25, 2026 | 5.952B |
| August 24, 2026 | 5.889B |
| August 21, 2026 | 6.028B |
| August 20, 2026 | 5.834B |
| August 19, 2026 | 6.105B |
| August 18, 2026 | 5.717B |
| August 17, 2026 | 5.790B |
| August 14, 2026 | 5.606B |
| August 13, 2026 | 5.578B |
| August 12, 2026 | 5.779B |
| August 11, 2026 | 5.783B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.090B |
| Oncolytics Biotech, Inc. | 58.48M |
| Sangamo Therapeutics, Inc. | 37.32M |
| Sarepta Therapeutics, Inc. | 2.282B |
| Anixa Biosciences, Inc. | 77.73M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -79.06M |
| Revenue (Quarterly) | 1.157M |
| Total Expenses (Quarterly) | 80.21M |
| EPS Diluted (Quarterly) | -0.8963 |
| Gross Profit Margin (Quarterly) | -239.2% |
| Profit Margin (Quarterly) | -6.83K% |
| Earnings Yield | -4.33% |
| Normalized Earnings Yield | -4.332 |